12,928 research outputs found
Infections in dermatopathology: Emerging frontiers
No full textSignificant difficulties continue to exist in the diagnosis of many infectious diseases in dermatopathology. Identifying pathogens in skin biopsies using conventional diagnostic techniques such as microscopy and tissue culture has its limitations. In recent times, molecular techniques including immunohistochemistry, polymerase chain reaction, and in situ hybridization have emerged as useful tools in the diagnosis of cutaneous infections that are challenging and ambiguous on conventional histopathology, thus improving our diagnostic accuracy. In this review, we highlight the main molecular techniques that have been used and continue to evolve in the diagnosis of mucocutaneous infectious diseases and discuss their applicability. Copyright © 2012 by Lippincott Williams and Wilkins.Abbas O, 2011, J EUR ACAD DERMATOL, V25, P33, DOI 10.1111-j.1468-3083.2010.03684.x; Abdalla CMZ, 2009, INT J DERMATOL, V48, P27, DOI 10.1111-j.1365-4632.2009.03807.x; Alam M, 2003, J AM ACAD DERMATOL, V48, P385, DOI 10.1067-mjd.2003.184; Annunziato P, 1996, CLIN DIAGN VIROL, V7, P69, DOI 10.1016-S0928-0197(96)00252-8; ARNOLDI J, 1992, LAB INVEST, V66, P618; Arora SK, 2000, BRIT J DERMATOL, V142, P72, DOI 10.1046-j.1365-2133.2000.03244.x; Aurelian L, 2003, Dermatol Online J, V9, P1; Avidor B, 2001, AM J CLIN PATHOL, V115, P900; Behrhof W, 2008, J CLIN PATHOL, V61, P390, DOI 10.1136-jcp.2007.046714; BERKHOUT RJM, 1995, J CLIN MICROBIOL, V33, P690; Biliris KA, 2000, CANCER LETT, V161, P83, DOI 10.1016-S0304-3835(00)00596-6; Braun-Falco M, 2009, EXP DERMATOL, V18, P12, DOI 10.1111-j.1600-0625.2008.00805.x; Buffet M, 2007, J INVEST DERMATOL, V127, P2345, DOI 10.1038-sj.jid.5700888; Burnett JW, 2008, ARCH DERMATOL, V144, P902, DOI 10.1001-archderm.144.7.902; CARL M, 1990, ANN NY ACAD SCI, V590, P439, DOI 10.1111-j.1749-6632.1990.tb42252.x; Carlson JA, 2008, J AM ACAD DERMATOL, V59, P279, DOI 10.1016-j.jaad.2008.03.020; Chae GT, 2002, J MED MICROBIOL, V51, P417; Chen YH, 2001, J FORMOS MED ASSOC, V100, P244; Cheuk W, 2004, AM J CLIN PATHOL, V121, P335, DOI 10.1309-B8TC0LBVH8XY5MFV; Chuang YH, 1997, BRIT J DERMATOL, V137, P276, DOI 10.1046-j.1365-2133.1997.18201916.x; Costa MRE, 2000, MED MYCOL, V38, P139, DOI 10.1080-744118710; Courtney JW, 2004, J CLIN MICROBIOL, V42, P3164, DOI 10.1128-JCM.42.7.3164-3168.2004; Dadzie OE, 2011, AM J DERMATOPATH, V33, P1, DOI 10.1097-DAD.0b013e3181d7a2c0; Dauden E, 2001, ARCH DERMATOL, V137, P443; Dayal R, 2007, INDIAN J PEDIATR, V74, P645, DOI 10.1007-s12098-007-0115-x; DUMLER JS, 1994, DERMATOL CLIN, V12, P25; Ecker DJ, 2008, NAT REV MICROBIOL, V6, P553, DOI 10.1038-nrmicro1918; Eyzaguirre E, 2008, ARCH PATHOL LAB MED, V132, P424, DOI 10.1043-1543-2165(2008)132[424:AOITI]2.0.CO;2; Forslund O, 1999, J GEN VIROL, V80, P2437; Fortina P, 2002, TRENDS MOL MED, V8, P264, DOI 10.1016-S1471-4914(02)02331-6; Fredricks DN, 1999, CLIN INFECT DIS, V29, P475; Gilbert GL, 2002, TRENDS MOL MED, V8, P280, DOI 10.1016-S1471-4914(02)02349-3; Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357; Grilli R, 1999, J AM ACAD DERMATOL, V41, P793; Gulley ML, 2001, J MOL DIAGN, V3, P1, DOI 10.1016-S1525-1578(10)60642-3; Gushi A, 2003, J DERMATOL SCI, V31, P143, DOI 10.1016-S0923-1811(03)00002-1; Hansmann Y, 2005, J CLIN MICROBIOL, V43, P3800, DOI 10.1128-JCM.43.8.3800-3806.2005; Harwood CA, 2000, J MED VIROL, V61, P289, DOI 10.1002-1096-9071(200007)61:3289::AID-JMV23.0.CO;2-Z; Hayden RT, 2003, DIAGN MOL PATHOL, V12, P21, DOI 10.1097-00019606-200303000-00003; Hayden RT, 2002, DIAGN MOL PATHOL, V11, P119, DOI 10.1097-00019606-200206000-00009; Hiroshige K, 2002, OTOL NEUROTOL, V23, P602, DOI 10.1097-00129492-200207000-00034; Hoang MP, 2004, J CUTAN PATHOL, V31, P595, DOI 10.1111-j.0303-6987.2004.00236.x; Hu S, 2003, J CLIN MICROBIOL, V41, P1414, DOI 10.1128-JCM.41.4.1414-1418.2003; Isotalo PA, 2009, DIAGN MOL PATHOL, V18, P183, DOI 10.1097-PDM.0b013e31818b3716; Johnson TM, 1999, J AM ACAD DERMATOL, V41, P867, DOI 10.1016-S0190-9622(99)70355-5; Kampirapap K, 1998, INT J LEPROSY, V66, P16; Kanbe T, 2005, J DERMATOL SCI, V38, P99, DOI 10.1016-j.jdermsci.2004.12.024; Komatsu Tatiana Lucianelli, 2005, Braz Oral Res, V19, P317, DOI 10.1590-S1806-83242005000400015; Lampert A, 2000, ANN DERMATOL VENER, V127, P40; LARSEN SA, 1995, CLIN MICROBIOL REV, V8, P1; Lebech AM, 2002, APMIS S, V105, P1; Lilie HM, 2002, J EUR ACAD DERMATOL, V16, P53, DOI 10.1046-j.0926-9959.2001.00351.x; Lindsley MD, 2001, J CLIN MICROBIOL, V39, P3505, DOI 10.1128-JCM.39.10.3505-3511.2001; Liu D, 2002, J MED MICROBIOL, V51, P117; Liu H, 2001, J CLIN MICROBIOL, V39, P1941, DOI 10.1128-JCM.39.5.1941-1946.2001; Liu HJ, 2006, J CUTAN PATHOL, V33, P551, DOI 10.1111-j.1600-0560.2006.00438.x; Luo GZ, 2002, J CLIN MICROBIOL, V40, P2860, DOI 10.1128-JCM.40.8.2860-2865.2002; Mahboudi F, 2002, SCAND J INFECT DIS, V34, P756, DOI 10.1080-0036554021000026930; Margall N, 1996, BRIT J DERMATOL, V135, P231, DOI 10.1111-j.1365-2133.1996.tb01152.x; Martin-Ezquerra, 2009, HUM PATHOL, V40, P624; Mascaro JM, 2008, DERMATOL CLIN, V26, P439, DOI 10.1016-j.det.2008.05.007; Massung RF, 2003, J CLIN MICROBIOL, V41, P717, DOI 10.1128-JCM.41.2.717-722.2003; Matar GM, 1999, J CLIN MICROBIOL, V37, P4045; McEwen JG, 2000, MED MYCOL, V38, P189, DOI 10.1080-mmy.38.s1.189.197; Montalvo AM, 2010, PARASITOLOGY, V137, P1159, DOI 10.1017-S0031182010000089; Montone KT, 2010, DIAGN MOL PATHOL, V19, P99, DOI 10.1097-PDM.0b013e3181b3aa55; Montone KT, 2009, AM J CLIN PATHOL, V132, P866, DOI 10.1309-AJCPUBQ1QFRRX7MY; Moreno C, 2003, J AM ACAD DERMATOL, V48, P376, DOI 10.1067-mjd.2003.90; Nakajima N, 2003, AM J PATHOL, V162, P381, DOI 10.1016-S0002-9440(10)63833-3; Natrajan M, 2004, INT J LEPROSY, V72, P296, DOI 10.1489-0020-7349(2004)72296:ISHITH2.0.CO;2; Nikkels AF, 2007, AM J CLIN DERMATOL, V8, P79, DOI 10.2165-00128071-200708020-00003; NIKKELS AF, 1993, VIRCHOWS ARCH A, V422, P121, DOI 10.1007-BF01607163; NIKKELS AF, 1995, J MED VIROL, V47, P342, DOI 10.1002-jmv.1890470409; Nuovo GJ, 2000, AM J SURG PATHOL, V24, P1400, DOI 10.1097-00000478-200010000-00010; Nuovo M, 2001, J CUTAN PATHOL, V28, P248, DOI 10.1034-j.1600-0560.2001.028005248.x; Giorgio S, 1996, Rev Soc Bras Med Trop, V29, P419; Pala S, 2000, Int J STD AIDS, V11, P823; Park DY, 2003, ARCH PATHOL LAB MED, V127, P326; PERIS K, 1994, ARCH DERMATOL RES, V286, P364, DOI 10.1007-BF00371794; Pietravalle M, 1999, MICROBIOLOGICA, V22, P99; Quiros E, 1996, J CLIN PATHOL, V49, P889, DOI 10.1136-jcp.49.11.889; Quiros E, 2000, J CLIN LAB ANAL, V14, P133, DOI 10.1002-1098-2825(2000)14:4133::AID-JCLA13.0.CO;2-7; Rahaus M, 2003, J VIROL METHODS, V107, P257, DOI 10.1016-S0166-0934(02)00250-1; Reiss E, 1998, MED MYCOL, V36, P249; Robin YM, 2004, AM J CLIN PATHOL, V121, P330, DOI 10.1309-96U16LRRAN5HWWVE; Russell FM, 2002, J PAEDIATR CHILD H, V38, P311, DOI 10.1046-j.1440-1754.2002.00801.x; Santos AR, 2001, MEM I OSWALDO CRUZ, V96, P1129; Schell BJ, 2001, J AM ACAD DERMATOL, V45, P49, DOI 10.1067-mjd.2001.113460; SEXTON DJ, 1994, AM J TROP MED HYG, V50, P59; Sra KK, 2005, ARCH DERMATOL, V141, P225, DOI 10.1001-archderm.141.2.225; Sra KK, 2005, J AM ACAD DERMATOL, V53, P749, DOI 10.1016-j.jaad.2004.08.052; Stankiewicz E, 2009, MODERN PATHOL, V22, P1160, DOI 10.1038-modpathol.2009.77; Tan SH, 2001, ANN ACAD MED SINGAP, V30, P3; THOMPSON CH, 1990, PATHOLOGY, V22, P181; Torres P, 2003, LEPROSY REV, V74, P18; Toyoshima Marcos Tadashi Kakitani, 2006, Braz J Infect Dis, V10, P62, DOI 10.1590-S1413-86702006000100013; Troesch A, 1999, J CLIN MICROBIOL, V37, P49; VICTOR T, 1992, AM J DERMATOPATH, V14, P491; Wasserman J, 2009, ARCH PATHOL LAB MED, V133, P1053, DOI 10.1043-1543-2165-133.7.1053; Xu TH, 2010, MED MYCOL, V48, P161, DOI 10.3109-13693780903117481; Yee Y. C., 2002, SMJ Singapore Medical Journal, V43, P415; Yen A, 1997, ARCH DERMATOL, V133, P532, DOI 10.1001-archderm.133.4.532; Yoshida M, 2003, J VIROL METHODS, V109, P11, DOI 10.1016-S0166-0934(03)00036-3; Youssef R, 2002, J DERMATOL, V29, P404; Zaki SR, 1999, J INFECT DIS, V179, pS36; Zoechling N, 1997, BRIT J DERMATOL, V136, P683, DOI 10.1111-j.1365-2133.1997.tb03652.x; Zore A, 2002, WIEN KLIN WOCHENSCHR, V114, P6061
Path Assignment and Admission Control to Satisfice Multiple Service Requirements in ATM Networks
No full text
Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection.
No full textBACKGROUND: Two receptor chains, IL-10RA and IL-10RB, are known to mediate the functions of interleukin-10 (IL-10), which has been shown to be involved in the progression of persistent hepatitis C virus (HCV) infection. Little information is available on the role of host genetic variation in IL-10 receptor genes and outcome of HCV infection. IL-22, an IL-10 homologue, shares the IL-10RB receptor chain with IL-10 and has antiviral properties. We investigated the possible role of polymorphisms in the IL-10RA and IL-22 genes in hepatitis C disease pathogenesis. METHODS: This study population consisted of 631 HCV patients, recruited from several hepatology clinics across Europe. We genotyped four single-nucleotide polymorphisms (SNPs) in the IL-10RA and six SNPs in the IL-22 gene by ligation detection reaction or restriction fragment length polymorphism. Outcome of HCV infection was assessed according to viral clearance, treatment response, severity of fibrosis and overall inflammation. CONCLUSIONS: Variation in IL-10RA appeared to be correlated with response to treatment and inflammation. Two SNPs in IL-22 affected treatment response and viral clearance respectively. We furthermore report on allele and haplotype frequencies and linkage disequilibrium for IL-10RA and IL-22. Our results indicate that genetic variation in these genes may play a modulatory role in the outcome of hepatitis C infection
Inducible nitric oxide synthase gene (NOS2A) haplotypes and the outcome of hepatitis C virus infection.
No full textInducible nitric oxide synthase (iNOS) is an important molecule involved in the host defense against infectious agents. iNOS is encoded by the NOS2A gene and well-defined haplotypes exist with respect to this gene. We examined whether these haplotypes were associated with the outcome of hepatitis C virus (HCV) infection in 619 Caucasian patients from seven European liver centres. We observed five major haplotypes: (-277A)+(-1026G)+(-1659C): haplotype 1; (-277G)+(-1026T)+(-1659C): haplotype 2; (-277G)+(-1026G)+(-1659C): haplotype 3; (-277G)+(-1026T)+(-1659T): haplotype 4; and (-277A)+(-1026T)+(-1659C): haplotype 5. Distributions of these haplotypes are comparable with those of previous studies. Homozygotes for haplotype 2 or those with haplotypes 2/4 were more likely than those with the 1/1 (wild type) combination to have self-limiting infections (odds ratios (OR)=3.43; 95% confidence intervals (95% CI): 1.10-8.0; P=0.0206 and OR=5.15; 95% CI: 1.32-14.32; P=0.0018, respectively). Conversely, carriage of haplotype 1 was associated with the lack of self-limiting disease (OR=0.48; 95% CI: 0.27-0.83; P=0.009). The effect was mainly among males (OR=0.41; 95% CI: 0.182-0.942; P=0.031 for males, and OR=0.55; 95% CI: 0.24-1.37; P=0.136 for women). Carriage of haplotype 1 was not associated with initial response (P=0.268) or sustained response (P>0.171). Combinations of haplotypes 1/4 were more likely to respond to interferon monotherapy in comparison of initial responders to nonresponders (OR=2.25; 95% CI: 1.05-5.68; P=0.0275)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
No full textMultiple sclerosis is a common disease of the central nervous system in which the interplay between inflammatory and neurodegenerative processes typically results in intermittent neurological disturbance followed by progressive accumulation of disability. Epidemiological studies have shown that genetic factors are primarily responsible for the substantially increased frequency of the disease seen in the relatives of affected individuals, and systematic attempts to identify linkage in multiplex families have confirmed that variation within the major histocompatibility complex (MHC) exerts the greatest individual effect on risk. Modestly powered genome-wide association studies (GWAS) have enabled more than 20 additional risk loci to be identified and have shown that multiple variants exerting modest individual effects have a key role in disease susceptibility. Most of the genetic architecture underlying susceptibility to the disease remains to be defined and is anticipated to require the analysis of sample sizes that are beyond the numbers currently available to individual research groups. In a collaborative GWAS involving 9,772 cases of European descent collected by 23 research groups working in 15 different countries, we have replicated almost all of the previously suggested associations and identified at least a further 29 novel susceptibility loci. Within the MHC we have refined the identity of the HLA-DRB1 risk alleles and confirmed that variation in the HLA-A gene underlies the independent protective effect attributable to the class I region. Immunologically relevant genes are significantly overrepresented among those mapping close to the identified loci and particularly implicate T-helper-cell differentiation in the pathogenesis of multiple sclerosis
- …
